<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214952</url>
  </required_header>
  <id_info>
    <org_study_id>Vonoprazan-5001</org_study_id>
    <secondary_id>JapicCTI-163177</secondary_id>
    <nct_id>NCT03214952</nct_id>
  </id_info>
  <brief_title>Drug Use Surveillance of Takecab for &quot;Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis&quot;</brief_title>
  <official_title>Drug Use Surveillance of Takecab Tablets for &quot;Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of vonoprazan tablets
      (Takecab tablets) in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in
      the routine clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Vonoprazan (Takecab). Vonoprazan is being
      tested to treat people who have gastric ulcer, duodenal ulcer, and reflux esophagitis.

      This study will look at the safety and efficacy of Vonoprazan in patients with gastric ulcer,
      duodenal ulcer, and reflux esophagitis in the routine clinical setting.

      The study will enroll approximately 3000 patients.

      â€¢ Vonoprazan 20 mg

      This multi-center trial will be conducted in Japan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who had one or more adverse drug reactions in patients with gastric ulcer and reflux esophagitis</measure>
    <time_frame>Up to 8 Weeks</time_frame>
    <description>Adverse drug reaction refers to adverse events related to administered drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who had one or more adverse drug reactions in patients with duodenal ulcer</measure>
    <time_frame>Up to 6 Weeks</time_frame>
    <description>Adverse drug reaction refers to adverse events related to administered drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic cure rates</measure>
    <time_frame>At the start of treatment (Week 0), and at the end of surveillance [up to 8 Weeks (gastric ulcer and reflux esophagitis) or 6 Weeks (duodenal ulcer)]</time_frame>
    <description>Endoscopic cure rates will be tabulated by target disease in patients for whom endoscopic findings at the start of treatment with Vonoprazan tablets (Takecab) and at the end of surveillance are described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with improvement rates of subjective symptoms</measure>
    <time_frame>At the start of treatment (Week 0), week 2, week 4, and at the end of surveillance [up to 8 Weeks (gastric ulcer and reflux esophagitis) or 6 Weeks (duodenal ulcer)]</time_frame>
    <description>Improvement rates of subjective symptoms will be tabulated by target disease in patients for whom the degree of subjective symptoms from the start of treatment with Vonoprazan tablets (Takecab) to the end of surveillance are described. Reporting data will be total percentage of participants who have subjective symptoms related to gastric ulcer, duodenal ulcer, and reflux esophagitis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>Vonoprazan 20 mg</arm_group_label>
    <description>The usual adult dosage for oral use is 20 mg of Vonoprazan administered once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use is administered for a total of 4 weeks of treatment, and if that dosing proves insufficient, the administration may be extended, but for no longer than 8 weeks of treatment. Participants will receive interventions as part of routine medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan tablets</description>
    <arm_group_label>Vonoprazan 20 mg</arm_group_label>
    <other_name>Takecab tablets</other_name>
    <other_name>TAK-438</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of participants with a diagnosis of gastric ulcer,
        duodenal ulcer, and reflux esophagitisand received dose of Takecab/Vonoprazan in the
        routine clinical setting.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with gastric ulcer, duodenal ulcer, and reflux esophagitis

        Exclusion Criteria:

          -  Participants with previous history of hypersensitivity to ingredients in Takecab
             tablets

          -  Participants taking atazanavir sulfate or rilpivirine hydrochloride

          -  Participants meeting the criteria of scarring stage (S1, S2) of endoscopic
             classification defined by Sakita and Miwa at the start of the treatment with Takecab
             tablets, in the case that the target disease is gastric ulcer or duodenal ulcer

          -  Participants meeting the criteria of Grade N or Grade M of Los Angeles classification
             (Hoshihara's modification) at the start of the treatment with Takecab tablets, in the
             case that the target disease is reflux esophagitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Takeda Selected Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

